These agents alone or combined with chemotherapy (chemoimmunotherapy) are now approved as first-line treatment for patients with advanced NSCLC without targetable driver mutations in epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)2. Here, ALK is linked to non-small cell lung carcinoma.